APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urotropin for Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Urotropin for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchUrotropin for Injection Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Urotropin for Injection Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Urotropin for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urotropin for Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Urotropin for Injection Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Urotropin for Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Urotropin for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Urotropin for Injection include Yantai Dongcheng North Pharmaceutical, Teva, Shanghai Tianwei Biopharmaceutical Co., Ltd., Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd., Qingdao Kangyuan Pharmaceutical, Ningbo Human Health Pharmaceutical Group, Ningbo Human Health Pharmaceutical, Merck and Maanshan Fengyuan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urotropin for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urotropin for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urotropin for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urotropin for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Urotropin for Injection Segment by Company

Yantai Dongcheng North Pharmaceutical

Teva

Shanghai Tianwei Biopharmaceutical Co., Ltd.

Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.

Qingdao Kangyuan Pharmaceutical

Ningbo Human Health Pharmaceutical Group

Ningbo Human Health Pharmaceutical

Merck

Maanshan Fengyuan Pharmaceutical

Livzon Group

Ferring GmbH

Livzon

IBSA Group

GenSci

Gedeon Richter

Urotropin for Injection Segment by Type

75 Unit

150 Unit

Urotropin for Injection Segment by Application

Hospital

Clinic

Urotropin for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urotropin for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urotropin for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urotropin for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urotropin for Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Urotropin for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Urotropin for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Urotropin for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Urotropin for Injection Industry Trends Table 2. Urotropin for Injection Industry Drivers Table 3. Urotropin for Injection Industry Opportunities and Challenges Table 4. Urotropin for Injection Industry Restraints Table 5. Global Urotropin for Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Urotropin for Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Urotropin for Injection Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Urotropin for Injection Sales Market Share by Manufacturers Table 9. Global Urotropin for Injection Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Urotropin for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Urotropin for Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Urotropin for Injection Manufacturers, Product Type & Application Table 13. Global Urotropin for Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Urotropin for Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 75 Unit Table 17. Major Manufacturers of 150 Unit Table 18. Global Urotropin for Injection Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Urotropin for Injection Sales by Type (2021-2026) & (k units) Table 20. Global Urotropin for Injection Sales by Type (2027-2032) & (k units) Table 21. Global Urotropin for Injection Sales Market Share by Type (2021-2026) Table 22. Global Urotropin for Injection Sales Market Share by Type (2027-2032) Table 23. Global Urotropin for Injection Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Urotropin for Injection Revenue by Type (2021-2026) & (k units) Table 25. Global Urotropin for Injection Revenue by Type (2027-2032) & (k units) Table 26. Global Urotropin for Injection Revenue Market Share by Type (2021-2026) Table 27. Global Urotropin for Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Global Urotropin for Injection Sales by Application 2021 VS 2025 VS 2032 (k units) Table 31. Global Urotropin for Injection Sales by Application (2021-2026) & (k units) Table 32. Global Urotropin for Injection Sales by Application (2027-2032) & (k units) Table 33. Global Urotropin for Injection Sales Market Share by Application (2021-2026) Table 34. Global Urotropin for Injection Sales Market Share by Application (2027-2032) Table 35. Global Urotropin for Injection Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Urotropin for Injection Revenue by Application (2021-2026) & (k units) Table 37. Global Urotropin for Injection Revenue by Application (2027-2032) & (k units) Table 38. Global Urotropin for Injection Revenue Market Share by Application (2021-2026) Table 39. Global Urotropin for Injection Revenue Market Share by Application (2027-2032) Table 40. Global Urotropin for Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 41. Global Urotropin for Injection Sales by Region (2021-2026) & (k units) Table 42. Global Urotropin for Injection Sales Market Share by Region (2021-2026) Table 43. Global Urotropin for Injection Sales Forecasted by Region (2027-2032) & (k units) Table 44. Global Urotropin for Injection Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 46. North America Urotropin for Injection Sales by Country (2021-2026) & (k units) Table 47. North America Urotropin for Injection Sales by Country (2027-2032) & (k units) Table 48. Europe Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. Europe Urotropin for Injection Sales by Country (2021-2026) & (k units) Table 50. Europe Urotropin for Injection Sales by Country (2027-2032) & (k units) Table 51. Asia Pacific Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Asia Pacific Urotropin for Injection Sales by Country (2021-2026) & (k units) Table 53. Asia Pacific Urotropin for Injection Sales by Country (2027-2032) & (k units) Table 54. South America, Middle East and Africa Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. South America, Middle East and Africa Urotropin for Injection Sales by Country (2021-2026) & (k units) Table 56. South America, Middle East and Africa Urotropin for Injection Sales by Country (2027-2032) & (k units) Table 57. Global Urotropin for Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Urotropin for Injection Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Urotropin for Injection Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Urotropin for Injection Revenue Market Share by Region (2021-2026) Table 61. Global Urotropin for Injection Revenue Market Share by Region (2027-2032) Table 62. Yantai Dongcheng North Pharmaceutical Company Information Table 63. Yantai Dongcheng North Pharmaceutical Business Overview Table 64. Yantai Dongcheng North Pharmaceutical Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Yantai Dongcheng North Pharmaceutical Urotropin for Injection Product Portfolio Table 66. Yantai Dongcheng North Pharmaceutical Recent Development Table 67. Teva Company Information Table 68. Teva Business Overview Table 69. Teva Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Teva Urotropin for Injection Product Portfolio Table 71. Teva Recent Development Table 72. Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Information Table 73. Shanghai Tianwei Biopharmaceutical Co., Ltd. Business Overview Table 74. Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio Table 76. Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Development Table 77. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Company Information Table 78. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Business Overview Table 79. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio Table 81. Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Recent Development Table 82. Qingdao Kangyuan Pharmaceutical Company Information Table 83. Qingdao Kangyuan Pharmaceutical Business Overview Table 84. Qingdao Kangyuan Pharmaceutical Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Qingdao Kangyuan Pharmaceutical Urotropin for Injection Product Portfolio Table 86. Qingdao Kangyuan Pharmaceutical Recent Development Table 87. Ningbo Human Health Pharmaceutical Group Company Information Table 88. Ningbo Human Health Pharmaceutical Group Business Overview Table 89. Ningbo Human Health Pharmaceutical Group Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Ningbo Human Health Pharmaceutical Group Urotropin for Injection Product Portfolio Table 91. Ningbo Human Health Pharmaceutical Group Recent Development Table 92. Ningbo Human Health Pharmaceutical Company Information Table 93. Ningbo Human Health Pharmaceutical Business Overview Table 94. Ningbo Human Health Pharmaceutical Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Ningbo Human Health Pharmaceutical Urotropin for Injection Product Portfolio Table 96. Ningbo Human Health Pharmaceutical Recent Development Table 97. Merck Company Information Table 98. Merck Business Overview Table 99. Merck Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Merck Urotropin for Injection Product Portfolio Table 101. Merck Recent Development Table 102. Maanshan Fengyuan Pharmaceutical Company Information Table 103. Maanshan Fengyuan Pharmaceutical Business Overview Table 104. Maanshan Fengyuan Pharmaceutical Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Maanshan Fengyuan Pharmaceutical Urotropin for Injection Product Portfolio Table 106. Maanshan Fengyuan Pharmaceutical Recent Development Table 107. Livzon Group Company Information Table 108. Livzon Group Business Overview Table 109. Livzon Group Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Livzon Group Urotropin for Injection Product Portfolio Table 111. Livzon Group Recent Development Table 112. Ferring GmbH Company Information Table 113. Ferring GmbH Business Overview Table 114. Ferring GmbH Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Ferring GmbH Urotropin for Injection Product Portfolio Table 116. Ferring GmbH Recent Development Table 117. Livzon Company Information Table 118. Livzon Business Overview Table 119. Livzon Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Livzon Urotropin for Injection Product Portfolio Table 121. Livzon Recent Development Table 122. IBSA Group Company Information Table 123. IBSA Group Business Overview Table 124. IBSA Group Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. IBSA Group Urotropin for Injection Product Portfolio Table 126. IBSA Group Recent Development Table 127. GenSci Company Information Table 128. GenSci Business Overview Table 129. GenSci Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. GenSci Urotropin for Injection Product Portfolio Table 131. GenSci Recent Development Table 132. Gedeon Richter Company Information Table 133. Gedeon Richter Business Overview Table 134. Gedeon Richter Urotropin for Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Gedeon Richter Urotropin for Injection Product Portfolio Table 136. Gedeon Richter Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Urotropin for Injection Distributors List Table 140. Urotropin for Injection Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Urotropin for Injection Product Image Figure 2. Global Urotropin for Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urotropin for Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Urotropin for Injection Sales (2021-2032) & (k units) Figure 5. Global Urotropin for Injection Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Urotropin for Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 75 Unit Image Figure 9. 150 Unit Image Figure 10. Global Urotropin for Injection Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Urotropin for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Urotropin for Injection Sales Market Share by Type (2021-2032) Figure 13. Global Urotropin for Injection Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Urotropin for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Urotropin for Injection Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Global Urotropin for Injection Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Urotropin for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Urotropin for Injection Sales Market Share by Application (2021-2032) Figure 21. Global Urotropin for Injection Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Urotropin for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Urotropin for Injection Revenue Market Share by Application (2021-2032) Figure 24. North America Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 25. North America Urotropin for Injection Sales Market Share by Country (2021-2032) Figure 26. U.S. Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 27. Canada Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 28. Mexico Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 29. Europe Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Urotropin for Injection Sales Market Share by Country (2021-2032) Figure 31. Germany Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 32. France Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 33. U.K. Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 34. Italy Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 35. Netherlands Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 36. Asia Pacific Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Urotropin for Injection Sales Market Share by Country (2021-2032) Figure 38. China Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 39. Japan Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 40. South Korea Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 41. Southeast Asia Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 42. India Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 43. Australia Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 44. South America, Middle East and Africa Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Urotropin for Injection Sales Market Share by Country (2021-2032) Figure 46. Brazil Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Africa Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 48. Saudi Arabia Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 49. Turkey Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 50. Argentina Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 51. UAE Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 52. Egypt Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 53. Chile Urotropin for Injection Sales and Growth Rate (2021-2032) & (k units) Figure 54. Global Urotropin for Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Urotropin for Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Urotropin for Injection Revenue (2021-2032) & (US$ Million) Figure 57. North America Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Urotropin for Injection Revenue (2021-2032) & (US$ Million) Figure 59. Europe Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Urotropin for Injection Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Urotropin for Injection Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Urotropin for Injection Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Urotropin for Injection Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • 75 Unit
  • 150 Unit
Applications
  • Hospital
  • Clinic
Companies covered
  • Yantai Dongcheng North Pharmaceutical
  • Teva
  • Shanghai Tianwei Biopharmaceutical Co., Ltd.
  • Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
  • Qingdao Kangyuan Pharmaceutical
  • Ningbo Human Health Pharmaceutical Group
  • Ningbo Human Health Pharmaceutical
  • Merck
  • Maanshan Fengyuan Pharmaceutical
  • Livzon Group
  • Ferring GmbH
  • Livzon
  • IBSA Group
  • GenSci
  • Gedeon Richter

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Urotropin for Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Urotropin for Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Urotropin for Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Urotropin for Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Urotropin for Injection Market Dynamics
  1. 2.1 Urotropin for Injection Industry Trends
  2. 2.2 Urotropin for Injection Industry Drivers
  3. 2.3 Urotropin for Injection Industry Opportunities and Challenges
  4. 2.4 Urotropin for Injection Industry Restraints
3 Urotropin for Injection Market by Manufacturers
  1. 3.1 Global Urotropin for Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Urotropin for Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Urotropin for Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Urotropin for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Urotropin for Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Urotropin for Injection Manufacturers, Product Type & Application
  7. 3.7 Global Urotropin for Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Urotropin for Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Urotropin for Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Urotropin for Injection Tier 1, Tier 2, and Tier 3
4 Urotropin for Injection Market by Type
  1. 4.1 Urotropin for Injection Type Introduction
  2. 4.1.1 75 Unit
  3. 4.1.2 150 Unit
  4. 4.2 Global Urotropin for Injection Sales by Type
  5. 4.2.1 Global Urotropin for Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Urotropin for Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Urotropin for Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Urotropin for Injection Revenue by Type
  9. 4.3.1 Global Urotropin for Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Urotropin for Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Urotropin for Injection Revenue Market Share by Type (2021-2032)
5 Urotropin for Injection Market by Application
  1. 5.1 Urotropin for Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Urotropin for Injection Sales by Application
  5. 5.2.1 Global Urotropin for Injection Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Urotropin for Injection Sales by Application (2021-2032)
  7. 5.2.3 Global Urotropin for Injection Sales Market Share by Application (2021-2032)
  8. 5.3 Global Urotropin for Injection Revenue by Application
  9. 5.3.1 Global Urotropin for Injection Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Urotropin for Injection Revenue by Application (2021-2032)
  11. 5.3.3 Global Urotropin for Injection Revenue Market Share by Application (2021-2032)
6 Global Urotropin for Injection Sales by Region
  1. 6.1 Global Urotropin for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urotropin for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Urotropin for Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Urotropin for Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Urotropin for Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Urotropin for Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Urotropin for Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Urotropin for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Urotropin for Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Urotropin for Injection Revenue by Region
  1. 7.1 Global Urotropin for Injection Revenue by Region
  2. 7.1.1 Global Urotropin for Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Urotropin for Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Urotropin for Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Urotropin for Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Urotropin for Injection Revenue (2021-2032)
  8. 7.2.2 North America Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Urotropin for Injection Revenue (2021-2032)
  11. 7.3.2 Europe Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Urotropin for Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Urotropin for Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Urotropin for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Yantai Dongcheng North Pharmaceutical
  2. 8.1.1 Yantai Dongcheng North Pharmaceutical Company Information
  3. 8.1.2 Yantai Dongcheng North Pharmaceutical Business Overview
  4. 8.1.3 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yantai Dongcheng North Pharmaceutical Urotropin for Injection Product Portfolio
  6. 8.1.5 Yantai Dongcheng North Pharmaceutical Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Urotropin for Injection Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Shanghai Tianwei Biopharmaceutical Co., Ltd.
  14. 8.3.1 Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Shanghai Tianwei Biopharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Tianwei Biopharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
  18. 8.3.5 Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd.
  20. 8.4.1 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Urotropin for Injection Product Portfolio
  24. 8.4.5 Shanghai Shanghai Pharmaceutical First Biochemical Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Qingdao Kangyuan Pharmaceutical
  26. 8.5.1 Qingdao Kangyuan Pharmaceutical Company Information
  27. 8.5.2 Qingdao Kangyuan Pharmaceutical Business Overview
  28. 8.5.3 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Qingdao Kangyuan Pharmaceutical Urotropin for Injection Product Portfolio
  30. 8.5.5 Qingdao Kangyuan Pharmaceutical Recent Developments
  31. 8.6 Ningbo Human Health Pharmaceutical Group
  32. 8.6.1 Ningbo Human Health Pharmaceutical Group Company Information
  33. 8.6.2 Ningbo Human Health Pharmaceutical Group Business Overview
  34. 8.6.3 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ningbo Human Health Pharmaceutical Group Urotropin for Injection Product Portfolio
  36. 8.6.5 Ningbo Human Health Pharmaceutical Group Recent Developments
  37. 8.7 Ningbo Human Health Pharmaceutical
  38. 8.7.1 Ningbo Human Health Pharmaceutical Company Information
  39. 8.7.2 Ningbo Human Health Pharmaceutical Business Overview
  40. 8.7.3 Ningbo Human Health Pharmaceutical Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ningbo Human Health Pharmaceutical Urotropin for Injection Product Portfolio
  42. 8.7.5 Ningbo Human Health Pharmaceutical Recent Developments
  43. 8.8 Merck
  44. 8.8.1 Merck Company Information
  45. 8.8.2 Merck Business Overview
  46. 8.8.3 Merck Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck Urotropin for Injection Product Portfolio
  48. 8.8.5 Merck Recent Developments
  49. 8.9 Maanshan Fengyuan Pharmaceutical
  50. 8.9.1 Maanshan Fengyuan Pharmaceutical Company Information
  51. 8.9.2 Maanshan Fengyuan Pharmaceutical Business Overview
  52. 8.9.3 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Maanshan Fengyuan Pharmaceutical Urotropin for Injection Product Portfolio
  54. 8.9.5 Maanshan Fengyuan Pharmaceutical Recent Developments
  55. 8.10 Livzon Group
  56. 8.10.1 Livzon Group Company Information
  57. 8.10.2 Livzon Group Business Overview
  58. 8.10.3 Livzon Group Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Livzon Group Urotropin for Injection Product Portfolio
  60. 8.10.5 Livzon Group Recent Developments
  61. 8.11 Ferring GmbH
  62. 8.11.1 Ferring GmbH Company Information
  63. 8.11.2 Ferring GmbH Business Overview
  64. 8.11.3 Ferring GmbH Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ferring GmbH Urotropin for Injection Product Portfolio
  66. 8.11.5 Ferring GmbH Recent Developments
  67. 8.12 Livzon
  68. 8.12.1 Livzon Company Information
  69. 8.12.2 Livzon Business Overview
  70. 8.12.3 Livzon Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Livzon Urotropin for Injection Product Portfolio
  72. 8.12.5 Livzon Recent Developments
  73. 8.13 IBSA Group
  74. 8.13.1 IBSA Group Company Information
  75. 8.13.2 IBSA Group Business Overview
  76. 8.13.3 IBSA Group Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 IBSA Group Urotropin for Injection Product Portfolio
  78. 8.13.5 IBSA Group Recent Developments
  79. 8.14 GenSci
  80. 8.14.1 GenSci Company Information
  81. 8.14.2 GenSci Business Overview
  82. 8.14.3 GenSci Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GenSci Urotropin for Injection Product Portfolio
  84. 8.14.5 GenSci Recent Developments
  85. 8.15 Gedeon Richter
  86. 8.15.1 Gedeon Richter Company Information
  87. 8.15.2 Gedeon Richter Business Overview
  88. 8.15.3 Gedeon Richter Urotropin for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Gedeon Richter Urotropin for Injection Product Portfolio
  90. 8.15.5 Gedeon Richter Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urotropin for Injection Value Chain Analysis
  2. 9.1.1 Urotropin for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urotropin for Injection Production Mode & Process
  6. 9.2 Urotropin for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urotropin for Injection Distributors
  9. 9.2.3 Urotropin for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst